• BX Home
  • Business of Biotechnology: [Page 9]

Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

BUSINESS OF BIOTECHNOLOGY

They're perfecting scientific developments that could cure the world's toughest diseases, improve food production, and even yield energy alternatives. This is the exciting world of biotechnology, where young companies fight to make innovative discoveries -- and to find new and innovative ways of funding those innovations.

Business of Biotechnology is part of Business Exchange, suggested by Arlene Weintraub. This topic contains 1,250 news and 4,718 blog items. Read updated news, blogs, and resources about Business of Biotechnology. Find user-submitted articles and reactions on Business of Biotechnology from like-minded professionals.

Most Active

The most active stories in this topic based on user activity.

Strategies for Optimising Your Bioequivalence Studies by Pharma IQmore

Pharma IQ caught up with Dr. Ole Østerberg, Clinical Research Scientist at NeuroSearch, ahead of the Bioequivalence and...

CMO - Client Relationships: Extremes & Standardisationmore

Ian Anderson Director, External Networks, M&S Business Unit Norgine, spoke to Pharma IQ about the evolution of the...

Analyst Picks and Pans: Amgen, Coinstar, American Woodmarkmore

Wall Street pored over new trial results for Amgen's anemia drug Aranesp on Aug. 26

My view: Congress can steer clear of life sciences more

Our nation's economy is in a recession. People are feeling the pain of job losses and working harder to make ends meet.

eCTD Continues Rise to Global Prominencemore

The ability to meet standards and regulatory approval is nowhere more important than in the pharmaceutical industry.

Getting eCTD Submissions Rightmore

While technology has undoubtedly had an impact on the techniques pharmaceutical firms use to develop new drugs, the...

7 Unique Challenges Facing the US Generic Pharma Industrymore

Vincent Andolina, VP Regulatory Affairs at GeneraMedix Inc identities the key risks facing the US generic drug industry

3 Essential Tips for Finding the Right CMO: From a Specialist Pharma P...more

Finding a suitable contract manufacturing organisation (CMO) that meets your business needs, can be an expensive and...

Amgen R&D Chief Takes Your Questionsmore

Questions for the pharma industry? Ask Roger Perlmutter, EVP of R&D at Amgen

Identifying the Key Challenges of Pharmaceutical Innovation: IFPMA Rep...more

Significant advances in medical treatment worldwide have helped people live longer and better lives. Mortality and...

The Real Reason Big Pharma Mergers Are Wisemore

The giants of the pharmaceutical industry may have found their salvation in the wave of consolidation.

‘Core Competencies to Expect from a Sterile CMO' Presented by Holliste...more

At the June 2010 Global Pharmaceutical Contract Manufacturing Convention in London, England, sterile fill/finish...

Harvard Medical School in Ethics Quandarymore

Students are questioning the financial relationships their professors have with drug companies.

Dire Stats For Biotechmore

he Biotech Industry Organization (BIO) this morning released a set of statistics that give a rather dire snapshot of...

Carl Icahn eyes Biotech leader Genzyme Corpmore

Pressure on Henri A. Termeer, chief executive of American biotechnology giant Genzyme Corporation (NASDAQ: GENZ), has...

Carl Icahn Resents his Corporate Raider Imagemore

Carl Icahn attempted a hostile acquisition of the Hollywood studio Lionsgate Entertainment. According to a recent New...

Eli Lilly in Talks to Acquire ImClonemore

Lilly is reportedly offering $6.1 billion for the maker of cancer drug Erbitux.

Failed Drug Trials Rarely Publishedmore

New research shows that studies suggesting drugs are ineffective are often not published by medical journals.

Will Denosumab Strengthen Amgen's Bones?more

An osteoporosis drug boosts the biotech giant's prospects.

Drugmakers Sweeten Deals for Biotech Groupsmore

The credit crisis and resulting stock swoon may make it easier for drugmakers to acquire biotech companies.

Merged Roche-Genentech shakes top mgmtmore

Pascal Soriot, the man charged with integrating Roche Holding AG (SWX:ROG) and Genentech Inc. -- alongside former...

Biotech bargains may be out theremore

Biotechnology dealmakers are swooping into San Francisco this week for the industry's annual kickoff conference,...

Injured Agraquest Biotech Worker David Bell Tells His Storymore

The biotech industry employs hundreds of thousands of workers in the United States yet the health and safety of workers...

Takeda to Pay Amylin Up to $1 Billion to Develop Obesity Drugsmore

Nov. 2 (Bloomberg) -- Takeda Pharmaceutical Co., maker of the world’s best-selling diabetes drug, agreed to pay as much...

So You Want to Get Funded?more

According to the National Venture Capital Assn. (NVCA), total venture capital investment for the first quarter of this...

Topic Feed: Most active content in Business of Biotechnology

Top Sources: Business of Biotechnology

  • investorideas.com
  • bioedgeconsulting.com
  • Biotech Blog
  • bloomberg.com
  • News
  • youtube.com
  • contrarianprofits.com
  • Forbes.com
  • industry.bnet.com
  • Health Beat

Most Active Users in this Topic

see all contributors in Business of Biotechnology

Featured White Papers

Post a Job

Jobs in this Topic

Process Sciences Associate Drug Product Regeneron | Rensselaer, NY
Posted: May 8
SOFTWARE ENGINEER at exciting biotech company! Adaptive Biotechnologies | Seattle, WA
Posted: Apr 19
Chief Medical Officer (CMO) for Pharma/Biotech Epc Search International | North Carolina
Posted: Apr 18

Report comment contains invalid characters. ()
cancel
Search Cancel